Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Janney Capital Downgrades DepoMed Inc (DEPO) to Neutral
July 30, 2015 9:28 AM EDTJanney Capital downgraded DepoMed Inc (NASDAQ: DEPO) from Buy to Neutral.
For an analyst ratings summary and ratings history on DepoMed Inc click here. For more ratings news on DepoMed Inc click here.
Shares of DepoMed Inc closed at $31.87 yesterday.
... MoreRBC Capital Downgrades DepoMed Inc (DEPO) to Sector Perform
July 30, 2015 6:46 AM EDTRBC Capital downgraded DepoMed Inc (NASDAQ: DEPO) from Outperform to Sector Perform with a price target of $32.00 (from $26.00).
For an analyst ratings summary and ratings history on DepoMed Inc click here. For more ratings news on DepoMed Inc click here.
Shares of DepoMed Inc closed at $31.87 yesterday.
... MoreDepomed (DEPO) Tops Q2 EPS by 27c; Boosts FY15 Outlook
July 29, 2015 4:07 PM EDTDepomed (NASDAQ: DEPO) reported Q2 EPS of $0.27, $0.27 better than the analyst estimate of $0.00. Revenue for the quarter came in at $94.3 million versus the consensus estimate of $88.33 million.
Depomed sees FY2015 revenue of $320-340 million, versus prior guidance of $335-310 million. The company sees... More
Depomed (DEPO) Board Rejects Horizon Pharma's (HZNP) Revised Takeover Proposal
July 29, 2015 4:05 PM EDTDepomed (NASDAQ: DEPO) announced that its Board of Directors, after careful consideration and with the assistance of its independent financial and legal advisors, has unanimously rejected the purported revised, highly conditional, unsolicited and non-binding proposal from Horizon Pharma plc (NASDAQ: HZNP) ("Horizon") to acquire all of the outstanding shares of Depomed in an all-stock transaction (the "July 21 Proposal").
The Depomed Board concluded that the July 21 Proposal is inadequate and not in the best interests of Depomed and its shareholders. The Depomed Board believes that the... More
